2011

Opting to Track Early Prostate Cancer.

A December 20th article by Associated Press medical writer Lauran Neergaard illustrated the difference between “watchful waiting” and “active surveillance” for men diagnosed with early-stage prostate cancer. Most of the 240,000 cases of prostate cancer diagnosed annually in the United States are in the “low-risk” category. Yet 90% of these men seek immediate treatment and more »

November News Items: 1) Watchful-Waiting; 2) New drug TAK-700; 3) Use of Cryotherapy After Failure of Radiation or Brachytherapy.

1) The November 16th, 2011 issue of the Newsletter from Zero-The Project to End Prostate Cancer, published an interesting article from the New York Times entitled “A  Watch-and-Wait Prostate Cancer Treatment.”  The article focused on the PSA screening and subsequent actions that a man over the age of 70 can take to keep his prostate more »

MDV3100 Extends Life in Men Whose Prostate Cancer Had Failed Hormonal- and Chemotherapies.

Positive Phase 3 clinical trial results for the drug MDV3100 in men whose prostate cancers had progressed after failing hormonal therapy and chemotherapy have recently been reported in a special edition of the Prostate Cancer Foundation Newsletter, November 7th, 2011 (see http://www.pcf.org/site).  Such positive results were observed that the trial was stopped early and the more »

FDA Grants Fast Track Designation to Radium-223 Chloride (Alpharadin) for the Treatment of Hormone Refractory Prostate Cancer That Has Spread to the Bone.

At the annual American Society of Clinical Oncology (ASCO) meeting in Chicago in June 2011, the Prostate Cancer Foundation September 30th newsletter reported on promising Phase III clinical trial results for radium-223 chloride (alpharadin), an agent specifically being developed for cancer patients with bone metastases. The drug works by emitting small doses of alpha particle radiation that more »

URGENT ACTION NEEDED! Government Proposes Elimination of Prostate Cancer Testing. Does PSA Screening for Prostate Cancer Save Lives?

The United States Preventive Services Task Force (USPSTF), an independent panel appointed by the Federal cabinet-level Department of Health and Human Services (DHHS), is preparing a recommendation which would eliminate prostate cancer testing (PSA) for all men. The rationale cited by the government panel is that there is moderate or high certainty that PSA testing more »

Prostate Cancer Stem Cells: A New Target for Treating Hormone-Refractory Cancer.

It has been known for over 60 years that in general, prostate cancer cells respond to androgen deprivation (hormonal) therapy. At some point however, the prostate cells no longer respond (they become hormone-refractory) and levels of prostate-specific antigen (PSA) begin to rise. Treating this hormone-refractory prostate cancer remains a major challenge. There is now evidence more »

Sanibel, Florida; BJ Gabrielsen photo

Bone Scans for Metastatic Prostate Cancer

The most troubling thought for prostate cancer patients whose cancer has recurred after an initial radicalprostatectomy is the fact that there are PSA-producing cells located somewhere in our bodies. While subsequent treatments such as androgen deprivation (hormonal) therapy may keep these cells under control, there are undoubtedly micro-metastases somewhere in our bodies. When the controlling more »

NewsPulse, a Medical Resource from the Prostate Cancer Foundation. Biomarkers in Urine for the Detection of Prostate Cancer.

Sources of current medical information concerning prostate cancer are listed on this website under the section Medical Resources.  Recently, a new August 2011 electronic newsletter entitled NewsPulse was received from the Prostate Cancer Foundation. The issue contained very current information on specific diagnostic methods, biomarkers for cancer detection, targeted therapies and drugs under development, nutrition and more »

Information from Johns Hopkins: a) Use of Immunotherapies (Provenge, Prostvac) Against Prostate Cancer; and, b) Gleason Scores.

Provenge (sipuleucel-T) was the first approved prostate cancer therapy which uses a person’s immune system to fight the disease.  Its approval was limited to men with advanced prostate cancer who have not responded to other treatments like hormonal (androgen deprivation) therapy and are experiencing few or no symptoms. Cost and supply remain significant issues hindering more »

Good News!

My prostate-specific antigen (PSA) level was again below detectable limits, 0.01 ng/mL. The prostate cancer is still under control! God’s plan, presence, protection, power and promises again prevailed over my apprehension and fears. Christ’s perfect love truly never fails! The scene above overlooking Charlotte Harbor as it leads to the Gulf of Mexico is from a scenic more »

GOOD NEWS!!! New Regimens and Therapeutic Agents in the Pipeline; a Visit with my Oncologist.

Every six months, I have an appointment with my oncologist at the Moffitt Cancer Center, on the campus of the University of South Florida, in Tampa. Moffitt is a designated National Cancer Institute (NCI, National Institutes of Health, my former employer) Comprehensive Cancer Center, a highly-sought-after distinction. My oncologist had been highly recommended to me more »